



NEWS RELEASE

# Marinus Pharmaceuticals Announces Multiple Presentations at Upcoming Medical Meetings

10/11/2022

RADNOR, Pa.--(BUSINESS WIRE)-- **Marinus Pharmaceuticals**, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that four abstracts have been accepted for poster presentation at upcoming medical meetings in October. Details are as follows:

## 51st Child Neurology Society Annual Meeting: October 12-15; Cincinnati, Ohio

Poster #40: "Extended duration ganaxolone treatment for seizures associated with CDKL5 Deficiency Disorder: 1-year minimum open-label extension follow-up"

- Date and time: Thursday, October 13 from 12:30-2:00 p.m. ET and 5:30-7:00 p.m. ET

Poster #62: "Effect of ganaxolone on behaviors in children with the CDKL5 Deficiency Disorder"

- Date and time: Thursday, October 13 from 12:30-2:00 p.m. ET and 5:30-7:00 p.m. ET

## Neocritical Care Society 20th Annual Meeting: October 17-21; San Antonio, Texas

"Pharmacokinetic Study Evaluating Intravenous Ganaxolone Bolus in Healthy Adult Volunteers"

- Date and time: Poster Session 1, October 19 from 4:15-5:15 p.m. CT

"Pharmacodynamic Effects of Intravenous Ganaxolone Bolus in Healthy Adult Volunteers"

- Date and time: Poster Session 1, October 19 from 4:15-5:15 p.m. CT

## About Marinus Pharmaceuticals

Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company's commercial product, ZTALMY® (ganaxolone) oral suspension CV, has been approved by the U.S. FDA for the treatment of seizures associated with CDKL5 deficiency disorder in patients two years of age and older. The potential of ganaxolone is also being studied in other rare seizure disorders, including in Phase 3 trials in tuberous sclerosis complex and refractory status epilepticus. Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral formulations to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings. For more information visit [www.marinuspharma.com](http://www.marinuspharma.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20221011005478/en/): <https://www.businesswire.com/news/home/20221011005478/en/>

### Company:

Sasha Damouni Ellis

Vice President, Corporate Affairs & Investor Relations

Marinus Pharmaceuticals, Inc.

[sdamouni@marinuspharma.com](mailto:sdamouni@marinuspharma.com)

Source: Marinus Pharmaceuticals